Australia markets close in 2 hours 15 minutes
  • ALL ORDS

    7,749.20
    +3.30 (+0.04%)
     
  • ASX 200

    7,540.90
    +1.90 (+0.03%)
     
  • AUD/USD

    0.6922
    +0.0031 (+0.45%)
     
  • OIL

    74.92
    +0.81 (+1.09%)
     
  • GOLD

    1,886.40
    +6.90 (+0.37%)
     
  • BTC-AUD

    33,065.65
    -281.41 (-0.84%)
     
  • CMC Crypto 200

    524.99
    -0.14 (-0.03%)
     
  • AUD/EUR

    0.6441
    +0.0029 (+0.45%)
     
  • AUD/NZD

    1.0927
    +0.0009 (+0.08%)
     
  • NZX 50

    12,141.27
    -55.88 (-0.46%)
     
  • NASDAQ

    12,464.51
    -108.85 (-0.87%)
     
  • FTSE

    7,836.71
    -65.09 (-0.82%)
     
  • Dow Jones

    33,891.02
    -34.99 (-0.10%)
     
  • DAX

    15,345.91
    -130.52 (-0.84%)
     
  • Hang Seng

    21,461.71
    +239.55 (+1.13%)
     
  • NIKKEI 225

    27,754.36
    +60.71 (+0.22%)
     

Is This Biotech Stock a Buy Following a Landmark Approval?

Is This Biotech Stock a Buy Following a Landmark Approval?

Provention Bio (NASDAQ: PRVB) is a small-cap biotech whose shares have doubled in the past three months. The company can thank the expected and eventual approval of Tzield for that performance. In mid-November, Tzield became the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for the delay of the onset of type 1 diabetes (T1D) in at-risk patients.